Madrigal is a biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), also known as metabolic dysfunction associated steatohepatitis (MASH). Our first therapy, Rezdiffra (resmetirom), was granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of adults with NASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) and is being studied in a Phase 3 trial for the treatment of NASH with compensated cirrhosis.
Role Overview:
The Senior Analyst, Commercial Analytics will support a wide range of analytics functions, including patient services, marketing, channel, and payer analytics and report directly into the Directory of Analytics. This is an exciting opportunity to engage in advanced analytics projects, perform deep dives into data, and proactively identify opportunities across multiple business areas. The role is ideal for someone eager to learn, contribute to high-impact initiatives, and grow within a dynamic, data-driven environment.
Position Responsibilities:
- Conduct ad-hoc deep dives into commercial data to address specific business questions and deliver actionable insights.
- Support advanced analytics projects, such as predictive modeling, segmentation, and multivariate analysis, working alongside senior team members.
- Identify new opportunities and areas for improvement by analyzing data across patient services, marketing, channel, and payer functions in collaboration with analytics leads
- Develop and maintain dashboards and reports that track key performance metrics across commercial areas, ensuring clarity for both technical and non-technical audiences.
- Collaborate with cross-functional teams to gather data and insights, understanding key business drivers and aligning analytics efforts with business needs.
- Provide analytical support to senior leaders by translating complex data into meaningful insights and clear recommendations.
- Monitor trends and patterns in commercial data to proactively flag risks or opportunities to improve performance.
- Ensure data accuracy and consistency across analytics platforms, collaborating with data engineering and IT teams to resolve any data-related issues.
Qualifications and Skills Required:
- Bachelor’s degree in Business Analytics, Data Science, or a related field.
- 3+ years of experience in analytics, preferably in the pharmaceutical or healthcare industry.
- Strong skills in data analysis, with experience in handling large datasets and working with cross-functional teams.
- Proficiency in SQL, Excel, and data visualization tools like Tableau or Power BI.
- Experience with advanced analytics techniques (e.g., regression analysis, A/B testing) and a desire to grow technical expertise.
- Excellent communication skills, with the ability to present technical data clearly and concisely.
Growth Opportunity:
This role offers exposure to a broad range of commercial analytics functions, providing the opportunity to grow expertise in advanced analytics, strategic decision-making, and cross-functional collaboration. With experience, the successful candidate will be well-positioned to move into specialized or leadership roles within the organization.
Compensation:
Base salary is determined by several factors that include, but are not limited to, a successful candidate's qualifications, skills, education, experience, business needs, and market demands. The role may also be eligible for bonus, equity, and comprehensive benefits, which include flexible paid time off (PTO), medical, dental, vision, and life and disability insurance.
Top Skills
What We Do
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-β selective agonist that is designed to target key underlying causes of NASH in the liver. Resmetirom is currently being evaluated in two Phase 3 clinical studies, MAESTRO-NASH and MAESTRO-NAFLD-1, designed to demonstrate multiple benefits in patients with NASH. For more information, visit www.madrigalpharma.com